Completed PHASE2 INTERVENTIONAL 2-arm NCT00000588

Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone

Chelation Therapy of Iron Overload With Oral Pyridoxal Isonicotinoyl Hydrazone

Sponsor: Case Western Reserve University

Conditions Anemia (Iron-Loading) Beta-Thalassemia Hematologic Diseases Hemoglobinopathies Iron Overload Thalassemia

Updated 6 times since 2017 Last updated: Sep 16, 2022 Started: Jun 5, 1989 Primary completion: Mar 31, 1993 Completion: Mar 31, 1995

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Anemia (Iron-Loading) and Beta-Thalassemia and is currently completed. Case Western Reserve University leads this study, which shows 6 recorded versions since 1989 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Sep 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 1989

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Case Western Reserve University
National Heart, Lung, and Blood Institute (NHLBI)

Data source: Case Western Reserve University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.